Glaxo Wellcome's Second Act
Executive Summary
The company faces a series of challenges that attack head-on one of the most successful franchises in drug industry history. New approaches to treating ulcers, combination therapies that eradicate the bacteria that causes the disease rather than simply treat its symptoms, will likely lead to an overall decrease in the use of H2 antagonists. Even more threatening for Glaxo Wellcome is the pending genericization of Zantac (ranitidine). The question the company faces: will the same strategies that helpe
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.